GLP-1 Drug Vision Loss Lawsuit 2026: Complete Guide to Ozempic, Wegovy & NAION Claims

What Is the GLP-1 Vision Loss Lawsuit?

Millions of Americans take GLP-1 receptor agonist drugs for type 2 diabetes and weight loss. Brand names include Ozempic, Wegovy, and Rybelsus (made by Novo Nordisk), as well as Mounjaro, Trulicity, and Zepbound (made by Eli Lilly). These drugs work by mimicking a natural gut hormone to regulate blood sugar and suppress appetite.

In July 2024, a landmark study by Harvard Medical School researchers published in JAMA Ophthalmology found that patients taking semaglutide (the active ingredient in Ozempic and Wegovy) had a fourfold increased risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) — a devastating condition that causes sudden, often irreversible vision loss.

Despite this peer-reviewed research, Novo Nordisk has not updated its US drug labels to warn prescribers or patients of this risk. Lawsuits allege that both Novo Nordisk and Eli Lilly knew or should have known about the NAION risk and failed in their duty to warn.

What is NAION?

Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) occurs when blood flow to the optic nerve is suddenly interrupted, causing permanent damage. Unlike arteritic AION (which is related to inflammation), NAION strikes without warning, often when you wake up in the morning. Symptoms include:

• Sudden loss of vision in one eye upon waking
• Blurring or dimness in part or all of the visual field
• Loss of color vision or contrast sensitivity
• Altitudinal field defect (losing the upper or lower half of vision)
• No pain (unlike other optic nerve conditions)

NAION is usually permanent. There is no FDA-approved treatment that reliably restores lost vision. The second eye is affected in approximately 15–25% of patients within 5 years. The emotional and economic toll on patients — many of whom can no longer drive, work, or live independently — is severe.

The Harvard Study: What the Science Shows

The pivotal study — published in JAMA Ophthalmology in July 2024 by researchers at Mass Eye and Ear (a Harvard Medical School affiliate) — analyzed medical records of over 16,000 patients. Key findings:

• Patients with type 2 diabetes taking semaglutide had a 4.28x higher risk of NAION compared to those taking other diabetes medications
• Patients taking semaglutide for obesity/weight loss had a 7.64x higher risk compared to those on other weight-loss medications
• The association persisted after controlling for other known NAION risk factors
• Researchers called for inclusion of NAION as a potential adverse event on GLP-1 drug labels

This research formed the scientific backbone of the lawsuits now consolidated in MDL 3163.

Which Drugs Are Involved?

The following GLP-1 receptor agonist drugs are named in or relevant to the litigation:

Do You Qualify? Eligibility Criteria

To have a viable GLP-1 NAION claim, you generally need to show:

1. Drug use: A prescription history for one or more of the drugs listed above
2. Diagnosis: A clinical diagnosis of NAION confirmed by an ophthalmologist or neuro-ophthalmologist
3. Timing: NAION developed during or after GLP-1 use
4. No prior NAION: You had not been previously diagnosed with NAION before starting the drug
5. Statute of limitations: Your claim is within the deadline for your state

The Legal Claims: What Are Plaintiffs Alleging?

Plaintiffs in MDL 3163 allege several theories of liability against Novo Nordisk and Eli Lilly:

• Failure to warn: The drugs' labels did not adequately disclose the NAION risk, despite scientific evidence
• Negligence: Manufacturers failed to conduct adequate safety studies and post-market surveillance
• Design defect: The drugs' mechanism of action poses an unreasonable risk to optic nerve health
• Fraud/misrepresentation: Marketing downplayed or concealed known risks
• Breach of warranty: Express and implied warranties about safety were not met

Why the Early-Stage Timing Matters

MDL 3163 was formed in March 2026 — making this one of the newest major pharmaceutical MDLs in the country. Early-stage MDL participation has historically offered strategic advantages:

• Law firms filing early can influence bellwether trial selection
• Plaintiffs filing early establish strong claim documentation before records are lost
• Settlement negotiations often favor early claimants in compensation grids
• Statute of limitations is not an issue for most claimants at this stage

What Happens Next in MDL 3163?

Based on the typical MDL timeline, expect:

• 2026: Plaintiff fact sheets, medical record collection, initial discovery
• 2027: Expert discovery, Daubert motions on NAION causation science
• 2027–2028: Bellwether trial selection and preparation
• 2028+: First trials or global settlement negotiations

For more details, see our MDL 3163 litigation tracker.